Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

(PowerPoint)

3,375 views

Published on

Published in: Health & Medicine
  • Be the first to comment

(PowerPoint)

  1. 1. Fertility Preservation in 2008 Options for patients facing gonadotoxic therapies September 19, 2008 Emily S. Jungheim, M.D. Instructor Reproductive Endocrinology & Infertility Department of Obstetrics & Gynecology Washington University
  2. 2. Cancer treatment and fertility… <ul><li>Treatment for men & pre-menopausal women —most common breast, melanoma, cervical, non-Hodgkin’s lymphoma & leukemia </li></ul><ul><ul><li>Increased survival </li></ul></ul><ul><ul><li>Quality of life… </li></ul></ul><ul><ul><ul><li>Risks to fertility? </li></ul></ul></ul><ul><li>Gonadotoxic agents </li></ul><ul><ul><li>Chemotherapy </li></ul></ul><ul><ul><li>Radiation </li></ul></ul><ul><li>Surgical therapy </li></ul><ul><li>Time needed for endocrine therapy </li></ul>
  3. 3. Questions… <ul><li>Treatment effects on fertility? </li></ul><ul><li>Options for fertility preservation? </li></ul>
  4. 4. Addressing the need for information… <ul><li>2004 President’s Cancer Panel </li></ul><ul><ul><li>“ Report on Survivorship” </li></ul></ul><ul><ul><ul><li>Infertility a top concern </li></ul></ul></ul><ul><li>The American Society for Reproductive Medicine, 2004 </li></ul><ul><ul><li>Fertility Preservation Special Interest Group </li></ul></ul><ul><li>NICHD, 2005 </li></ul><ul><ul><li>Fertility preservation research section </li></ul></ul><ul><li>ASCO Recommendations on Fertility Preservation in Cancer Patients, 2006 </li></ul>
  5. 5. What can we offer men?
  6. 6. Effects of cancer treatment on male fertility Lee et al. JCO, 2006 ? <ul><li>Newer agents </li></ul>Only temporary reductions in counts at doses used in conventional regimens, but additive effects are possible <ul><li>Amacrine, Bleomycine, Dacarbazine, Daunorubicin, Epirubicin, Etoposide, Fludarabine, 5-Fluorouracil, 6-Mercaptopurine, Methotrexate, Mitoxantrone, Thioguanine </li></ul>Can be additive with above agents in causing prolonged azoospermia, but cause only temporary reductions in counts when used alone <ul><li>Doxorubicin, Thiotepe, Cytosine arabinoside, Vinblastine, Vincristine </li></ul>Prolonged azoospermia not often observed at indicated dose <ul><li>Carboplatin </li></ul>Azoospermia likely, but always given with other highly sterilizing agents <ul><li>Busulfan, Ifosfamide, BCNU, Nitrogen Mustard, Actinomycin D </li></ul>Azoospermia in adulthood after treatment before puberty <ul><li>BCNU, CCNU </li></ul>Prolonged azoospermia <ul><li>Radiation to the testes, Chlorambucil, Cyclophosphamide, Procarbazine, Melphalan, Cisplatin </li></ul>Effect on sperm Agents
  7. 7. Fertility preservation for men: Sperm Banking
  8. 8. How do we counsel? <ul><li>Try to bank sperm prior to therapy… </li></ul><ul><ul><li>Optimal counts </li></ul></ul><ul><li>Sperm quality before, during, and after completion of therapy? </li></ul><ul><ul><li>Evidence for increased risks of aneuploidy and DNA damage? </li></ul></ul><ul><ul><ul><li>Sperm—yes </li></ul></ul></ul><ul><ul><ul><li>Offspring—no </li></ul></ul></ul><ul><li>Keep in mind… </li></ul><ul><ul><li>Does the patient have a partner? </li></ul></ul><ul><ul><ul><li>Get the partner involved </li></ul></ul></ul><ul><ul><ul><li>Partner’s age </li></ul></ul></ul><ul><ul><li>Goals for family building </li></ul></ul>Tempest et al. Human Reproduction, 2008
  9. 9. Fertility preservation for men @ Washington University… Sperm banking <ul><li>Outpatient </li></ul><ul><ul><li>Consultation </li></ul></ul><ul><ul><ul><li>(314)-286-2400 </li></ul></ul></ul><ul><ul><li>ID testing </li></ul></ul><ul><ul><ul><li>HIV 1 & 2, Hep B & C, RPR </li></ul></ul></ul><ul><ul><li>Collection appointment </li></ul></ul><ul><ul><ul><li>Before 1 P.M. </li></ul></ul></ul><ul><ul><ul><li>(314) 286-2431 </li></ul></ul></ul><ul><li>Inpatient </li></ul><ul><ul><li>Call to arrange </li></ul></ul><ul><ul><ul><li>314-286-2400 </li></ul></ul></ul><ul><ul><ul><li>Rush ID testing </li></ul></ul></ul><ul><ul><ul><li>In-house consultation </li></ul></ul></ul><ul><ul><ul><li>Consent forms </li></ul></ul></ul><ul><ul><ul><li>Bring specimen within 1 hour of collection </li></ul></ul></ul><ul><ul><ul><ul><li>9 A.M. - 1 P.M. </li></ul></ul></ul></ul>
  10. 10. What’s next? <ul><li>Inseminations for partner if counts are adequate </li></ul><ul><li>If not? </li></ul><ul><ul><li>IVF with ICSI </li></ul></ul><ul><ul><ul><li>In vitro fertilization </li></ul></ul></ul><ul><ul><ul><li>Intracytoplasmic sperm injection </li></ul></ul></ul><ul><ul><ul><ul><li>1 sperm injected into 1 egg… </li></ul></ul></ul></ul>
  11. 11. What can we offer women?
  12. 12. Risks of Permanent Amenorrhea after Chemotherapy & Radiotherapy Lee et al. JCO, 2006 <ul><li>Taxanes </li></ul><ul><li>Oxaliplatin </li></ul><ul><li>Irinotecan </li></ul><ul><li>Monoclonal antibodies </li></ul><ul><li>Tyrosine kinase inhibitors </li></ul>? <ul><li>Vincristine </li></ul><ul><li>Methotrexate </li></ul><ul><li>5-fluorouracil </li></ul>Very low or no risk <ul><li>CHOP X 4-6 cycles </li></ul><ul><li>CVP </li></ul><ul><li>AML therapy (anthracycline/cytarabine) </li></ul><ul><li>ALL therapy (multi-agent) </li></ul><ul><li>CMF, CEF, CAF x 6 cycles in women age less than 30 </li></ul>Lower risk (<20%) <ul><li>CMF, CEF, CAF x 6 cycles in women age 30-39 </li></ul><ul><li>AC x 4 in women age 40 and older </li></ul>Intermediate risk <ul><li>Hematopoietic stem cell transplantation with cyclophosphamide/total body irradiation or cyclophosphmide/busulfan </li></ul><ul><li>External beam radiation to a field that includes the ovaries </li></ul><ul><li>CMF, CEF, CAF x 6 cycles in women age 40 and older </li></ul>High risk (>80%) Treatment Degree of Risk
  13. 13. Fertility preservation: the options for women… <ul><li>Standard care </li></ul><ul><ul><li>“ Embryo banking” </li></ul></ul><ul><ul><ul><li>Assisted reproduction with embryo freezing </li></ul></ul></ul><ul><li>Experimental </li></ul><ul><ul><li>“ Oocyte banking” </li></ul></ul><ul><ul><ul><li>Assisted reproduction with oocyte freezing </li></ul></ul></ul><ul><ul><li>Ovarian tissue freezing </li></ul></ul><ul><li>Require a partner </li></ul><ul><li>or donor sperm </li></ul><ul><li>Must be pubertal </li></ul><ul><li>Don’t require sperm </li></ul><ul><li>Must be pubertal </li></ul><ul><li>Don’t require sperm </li></ul><ul><li>Can be prepubertal </li></ul>
  14. 14. Assisted Reproductive Technologies for fertility preservation: “Emergency I.V.F.” <ul><li>Steps : </li></ul><ul><li>Controlled Ovarian Hyperstimulation </li></ul><ul><ul><li>Follicle stimulating hormone </li></ul></ul><ul><ul><ul><li>( + letrozole for women with estrogen-sensitive cancers) </li></ul></ul></ul><ul><li>Oocyte retrieval </li></ul>In Vitro Fertilization & Embryo Cryopreservation (allows for preimplantation genetic diagnosis) Oocyte Cryopreservation Washington University Experimental Protocol - OR-
  15. 15. Embryo and oocyte cryopreservation for fertility preservation… <ul><li>Cornell University (Azim et al, JCO 2008) </li></ul><ul><ul><li>79 patients with breast cancer using letrozole protocol </li></ul></ul><ul><ul><ul><li>Froze embryos or oocytes </li></ul></ul></ul><ul><ul><ul><li>Average peak E2: 406 </li></ul></ul></ul><ul><ul><ul><li>23 month follow up </li></ul></ul></ul><ul><ul><ul><li>Hazard ratio for recurrence 0.56 </li></ul></ul></ul><ul><li>Washington University: </li></ul><ul><ul><li>10 patients total (embryos only): </li></ul></ul><ul><ul><ul><li>Average age 29, 4 with children in the past </li></ul></ul></ul><ul><ul><ul><li>4 breast cancer, 2 rectal cancer, 2 uterine cancer, 1 lung cancer, 1 lymphoma </li></ul></ul></ul><ul><ul><li>Average peak estradiol in patients (5) undergoing Letrozole protocol: 455 </li></ul></ul>? limited # of embryos/oocytes?
  16. 16. Ovarian tissue cryopreservation… <ul><li>Patient can be prepubertal </li></ul><ul><li>Do not need sperm </li></ul><ul><li>Can be done quickly </li></ul><ul><ul><li>Tissue removed laparoscopically </li></ul></ul><ul><ul><ul><li>As an outpatient </li></ul></ul></ul><ul><ul><ul><ul><li>-OR- </li></ul></ul></ul></ul><ul><ul><ul><li>Coordinated with another procedure </li></ul></ul></ul><ul><ul><ul><li>Tissue brought to the IVF laboratory for freezing </li></ul></ul></ul>-Experimental protocol-
  17. 17. Ovarian tissue cryopreservation… <ul><li>Documented pregnancies & live births </li></ul><ul><ul><li>Case reports—tissue back into the pelvis </li></ul></ul><ul><li>Washington University Protocol </li></ul><ul><ul><li>First retrieval in 2001 </li></ul></ul><ul><ul><li>To date, no one has returned to use their tissue </li></ul></ul><ul><li>Oncofertility Network @ Northwestern University </li></ul><ul><ul><li>National Physicians Cooperative & Washington University </li></ul></ul><ul><li>Mechanism for: </li></ul><ul><li>Tissue storage at a national facility </li></ul><ul><li>Research on ovarian tissue freezing & </li></ul><ul><li>“ in vitro maturation” </li></ul><ul><li>Data sharing for most “up-to-date” information </li></ul><ul><li>Follow up data </li></ul>
  18. 18. National Physician’s Cooperative <ul><li>Eligibility criteria: </li></ul><ul><ul><li>Ages 18-41 facing treatment that will likely compromise ovarian function </li></ul></ul><ul><ul><li>Healthy enough for laparoscopic surgery </li></ul></ul><ul><ul><li>Functional ovaries (FSH<10) </li></ul></ul><ul><ul><li>Defer treatment for ~1 week </li></ul></ul>
  19. 19. Why this is important? <ul><li>Rapid advances in fertility treatment—this is possible… </li></ul>
  20. 20. Barriers… <ul><li>Timely and accurate information </li></ul><ul><ul><li>Coordinating care </li></ul></ul><ul><ul><li>Addressing the “unknowns” of fertility preservation technology </li></ul></ul><ul><li>COST </li></ul>Storage fees and further processing of ovarian tissue, ?Gestational carrier? Storage fees, oocyte fertilization, and embryo transfer, ?Gestational carrier? Storage fees and embryo transfer, ?Gestational carrier? Future Costs: Initial Cost: Options: ~$12,000 Ovarian tissue freezing ~$8,000 + medications IVF with oocyte freezing ~$10,000 + medications IVF with embryo cyropreservation
  21. 21. On the horizon… <ul><li>Wash U REI Website: http://www.infertility.wustl.edu/ </li></ul><ul><ul><li>Quick information for physicians and patients </li></ul></ul><ul><ul><li>Link to fertility preservation site on the way… </li></ul></ul><ul><li>Collaborative group? </li></ul><ul><ul><li>To address the “unknowns” </li></ul></ul><ul><ul><ul><li>Case discussion </li></ul></ul></ul><ul><ul><ul><li>Research studies </li></ul></ul></ul><ul><li>“ Patient navigator”? </li></ul><ul><ul><li>Facilitate referral and access </li></ul></ul><ul><li>Financial help? </li></ul><ul><ul><li>For emergency IVF, sperm cryopreservation, ovarian cryopreservation </li></ul></ul>
  22. 22. Resources for physicians & patients… <ul><li>Wash U. website link coming soon @ http://www.infertility.wustl.edu/ </li></ul><ul><li>Myoncofertility.org </li></ul>
  23. 23. Thank you!

×